Molecular Effects of L-dopa Therapy in Parkinson’s Disease
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is one of the most common neurological diseases in elderly people. The mean age of onset is 55 years of age, and the risk for developing PD increases 5-fold by the age of 70. In PD, there is impairment in both motor and nonmotor (NMS) functions. The strategy of PD motor dysfunction treatment is simple and generally based on the enhancement of dopaminergic transmission by means of the L-dihydroxyphenylalanine (L-dopa) and dopamine (DA) agonists. L-dopa was discovered in the early -60's of the last century by Hornykiewicz and used for the treatment of patients with PD. L-dopa treatment in PD is related to decreased levels of the neurotransmitter (DA) in striatum and ab-sence of DA transporters on the nerve terminals in the brain. L-dopa may also indirectly stimulate the receptors of the D1 and D2 families. Administration of L-dopa to PD patients, especially long-time therapy, may cause side effects in the form of increased toxicity and inflammatory response, as well as disturbances in biothiols metabolism. Therefore, in PD pa-tients treated with L-dopa, monitoring of oxidative stress markers (8-oxo-2'-deoxyguanosine, apoptotic proteins) and in-flammatory factors (high-sensitivity C-reactive protein, soluble intracellular adhesion molecule), as well as biothiol com-pounds (homocysteine, cysteine, glutathione) is recommended. Administration of vitamins B6, B12, and folates along with an effective therapy with antioxidants and/or anti-inflammatory drugs at an early stage of PD might contribute to improvement in the quality of the life of patients with PD and to slowing down or stopping the progression of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Intraneuronal dopamine-quinone synthesis: a review
Sulzer, D., & Zecca, L. (1999) · Neurotoxicity Research · doi:10.1007/bf03033289 · Cited by 284
Dopamine Oxidation and Autophagy
Muñoz, P., Huenchuguala, S., Paris, I., & Segura-Aguilar, J. (2012) · Parkinson's Disease · doi:10.1155/2012/920953 · Cited by 214 · cited 4×
“Another process probably leading to cell death in PD is autophagy [12, 13].”
BackgroundInfluential
Cited by
Biological effects of red beetroot and betalains: A review
Hadipour, E., Taleghani, A., Tayarani‐Najaran, N., & Tayarani‐Najaran, Z. (2020) · Phytotherapy Research · doi:10.1002/ptr.6653 · Cited by 165
Weis, S., Schwiertz, A., Unger, M. M., Becker, A., Faßbender, K., Ratering, S., Kohl, M., Schnell, S., Schäfer, K.-H., & Egert, M. (2019) · npj Parkinson s Disease · doi:10.1038/s41531-019-0100-x · Cited by 145
Pradhan, P., Majhi, O., Biswas, A., Joshi, V. K., & Sinha, D. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02942-8 · Cited by 44
Metadata
- Authors
- Dorszewska, J., Prendecki, M., Lianeri, M., & Kozubski, W.
- Venue
- Current Genomics
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-03-31
- Volume
- 15
- Issue
- 1
- Pages
- 11-17
- ISSN
- 1389-2029 (ISSN-L)
- OpenAlex
- W2059173785
- Cited by
- 95
- References
- 3
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Effects of L-dopa Therapy in Parkinson’s Disease. https://app.cochat.ai/papers/10.2174/1389202914666131210213042
- The paper
- Dorszewska, J., Prendecki, M., Lianeri, M., & Kozubski, W. (2014). Molecular Effects of L-dopa Therapy in Parkinson’s Disease. Current Genomics. https://doi.org/10.2174/1389202914666131210213042
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.